{"nctId":"NCT01102257","briefTitle":"Dry Eye Assessment and Management: Feasibility Study","startDateStruct":{"date":"2010-01"},"conditions":["Dry Eye Syndromes","Keratoconjunctivitis Sicca"],"count":23,"armGroups":[{"label":"Omega-3 EFA Supplement","type":"EXPERIMENTAL","interventionNames":["Drug: Omega-3 EFA Supplement"]},{"label":"Olive Oil","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Olive Oil"]}],"interventions":[{"name":"Omega-3 EFA Supplement","otherNames":["Fish oil supplements"]},{"name":"Olive Oil","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Sign and date the informed consent form approved by the IRB.\n2. ≥ 18 years of age\n3. Demonstrate at least 2 of the 4 following signs in the same eye at two consecutive visits (Visit 1: 7 - 21 days prior to randomization, and Visit 2: day of randomization).\n\n   1. Conjunctival staining present ≥ 1\n   2. Corneal fluorescein staining present ≥ 1\n   3. Tear film break up time (TFBUT) ≤ 7 seconds\n   4. Schirmer test ≤ 7 mm/5min\n4. Demonstrate symptoms of dry eye disease (OSDI score of at least 22 at screening visit and at least 15 at randomization visit).\n5. Use or desire to use artificial tears on average of 2 times per day in the 2 weeks preceding study entry (run in period). No newly diagnosed patients can be enrolled and if a new patient wants to participate, she/he must be put on tears and re-evaluated in 6 months.\n6. Intraocular pressure (IOP) ≥ 5 mmHg and ≤ 22 mmHg in each eye.\n7. Women of child-bearing potential must agree to use a reliable method of contraception during study participation, and must demonstrate a negative urine pregnancy test at screening visit.\n8. Be willing/able to return for all study visits and to follow instructions from the study investigator and his/her staff.\n9. Be able to swallow large, soft gelcaps\n\nExclusion Criteria:\n\n1. Patients who are allergic to ingredients of the active or placebo pills (fish, olive oil).\n2. Current diagnosis of ocular infection (e.g. bacterial, viral or fungal).\n3. History of ocular herpetic keratitis.\n4. Eye surgery (including cataract surgery) within 6 months prior to randomization.\n5. Previous LASIK surgery\n6. Pregnant or nursing/lactating\n7. Participation in a study of an investigational drug or device within the past 30 days.\n8. Recent (≤ 3 months) initiation of use of systemic corticosteroids or other immunosuppressive agent and/or is planning to change treatment during study participation\n9. Cognitive or psychiatric deficit that precludes informed consent or ability to perform requirements of the investigation.\n10. Contact lens wearers\n11. Use of glaucoma medication or history of surgery for glaucoma.\n12. Recent (≤ 3 months) insertion of punctual plugs.\n13. Using punctual plugs but unwilling to commit to their use for the duration of the study.\n14. Unwilling to commit to same brand of artificial tears throughout the study.\n15. Current use of EPA/DHA supplements in excess of 1 gram/day.\n16. Recent (≤ 6 months) initiation of use of Restasis.\n17. Use of Restasis but unwilling to commit to use of Restasis for the duration of the study.\n18. Discontinued use of Restasis within the last 3 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change on Ocular Surface Disease Index (OSDI)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change on Brief Ocular Discomfort Inventory (BODI)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change on Impact of Dry Eye on Everyday Life (IDEEL)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in Quality of Life Associated With Chronic Pain","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in the Ocular Surface","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in Schirmer's","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in Relevant Biomarkers: HLA-DR, MUC 5A, Cytokines","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"PRIMARY","title":"Change in REd Blood Cell(RBC) Membrane Fatty Acid(FA) Content","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.46","spread":null},{"groupId":"OG001","value":"0.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.49","spread":null},{"groupId":"OG001","value":"0.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.91","spread":null},{"groupId":"OG001","value":"-0.23","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":9},"commonTop":["watery eyes","thirst","nausea"]}}}